In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
1. A method for treating renal vein thrombosis in a subject, comprising:
administering into a kidney vein of the subject an effective amount of a gutless adenoviral vector comprising:
a polynucleotide encoding a functional thrombomodulin protein; and
regulatory elements operably linked to the polynucleotide,
wherein the gutless adenoviral vector comprises the nucleotide sequence of SEQ ID NO: 13 or SEQ ID NO: 15 and expresses the thrombomodulin protein in the kidney vein of the subject.
2. The method of claim 1 , wherein the gutless adenoviral vector is administered into a segment of the renal vein using a balloon catheter.
3. The method of claim 1 , wherein the gutless adenoviral vector is administered into the kidney vein using a stent.
4. The method of claim 1 , wherein the regulatory element is a constitutive promoter.
5. The method of claim 4 , wherein the constitutive promoter is a CMV promoter.
6. The method of claim 1 , wherein the gutless adenoviral vector comprises the nucleotide sequences of SEQ ID NO: 13 and SEQ ID NO: 15.
7. The method of claim 1 , wherein the thrombomodulin protein has the amino acid sequence of SEQ ID NO: 2.